TAE226

11/15/2007 - "The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma."
07/15/2018 - "Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma."
11/15/2007 - "Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma."

03/01/2008 - "In the present study, we studied the effect of a novel FAK inhibitor, TAE226 (Novartis, Inc.), on the breast cancer cell lines. "
03/01/2008 - "We used stable breast cancer cell lines overexpressing Src (MCF-7-Src and BT474-Src) or overexpressing EGFR (BT474-EGFR), and control breast cancer cell lines for the treatment with different doses of TAE226 drug. "
05/01/2011 - "Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo."
05/01/2011 - "Oral administration of TAE226 in mice significantly decreased bone metastasis and osteoclasts involved which were induced by MDA-MB-231 breast cancer cells and increased the survival rate of the mouse models of bone metastasis. "
05/01/2011 - "In this study, we have analyzed anti-tumor effects of the novel FAK Tyr(397) inhibitor TAE226 against bone metastasis in breast cancer by using TAE226. "

06/01/2007 - "As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-molecular weight inhibitor of FAK, TAE226, against human glioma cell lines. "
06/01/2007 - "TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. "
04/01/2007 - "Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas."
04/01/2007 - "More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model. "
06/01/2007 - "Together, these data demonstrate the potential benefit of TAE226 for glioma therapy."

12/01/2019 - "TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma."

12/01/2008 - "We examined the expression of mTOR and S6 in esophageal cancer cells (SEG-1) and normal esophageal epithelial cells (KOB-13) and the efficacy of TAE226 against SEG-1 cells. "
12/01/2008 - "Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment."
12/01/2008 - "TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells."